Neuronetics, Inc.
No enriched coverage for $STIM in the last 7 days.
Neuronetics (NASDAQ: STIM) said it held the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. The nearly 7,000-square-foot facility, overseen by Neuronetics CEO Geoffrey Grammer, is described as the largest Greenbrook center to date and intended to expand access to interventional psychiatry and support clinical innovation.
Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
Neuronetics (STIM) shares rose more than 28% Monday after BTIG initiated coverage with a Buy rating and a $5 price forecast, based on 2.5 times estimated sales. The article links the move to Neuronetics’ 2024 Greenbrook TMS acquisition, adding TMS and Spravato. It cites Q1 results: loss of 16 cents and sales of $34.454M.
Recent STIM coverage spans financial news, market movers and corporate actions.
In the last 30 days, STIM insiders filed 1 SEC Form 4 transaction — 1 purchase ($62K) and no sales. The most active reporter was Chernett Jorey with 1 filing.
The article is a corporate expansion/branding update with no disclosed financial metrics, guidance, or clinical outcomes.
The CFO appointment is a governance and execution-signal catalyst, with an upcoming earnings window.
The move is primarily catalyst-driven by fresh analyst initiation and a quantified valuation framework, with supportive Q1 fundamentals cited.
This is a corporate HR and compensation disclosure that can create modest, short-lived sentiment noise but is not a fundamental operating change.
The filing discloses an insider open-market buy by a large holder, but it is not tied to new company fundamentals.
alphai scores every news story that mentions STIM with an AI model for sentiment and relevance, and aggregates insider trades from Neuronetics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Neuronetics (NASDAQ: STIM) said it held the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. The nearly 7,000-square-foot facility, overseen by Neuronetics CEO Geoffrey Grammer, is described as the largest Greenbrook center to date and intended to expand access to interventional psychiatry and support clinical innovation.
2 min readBiotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
6 min readNeuronetics (STIM) shares rose more than 28% Monday after BTIG initiated coverage with a Buy rating and a $5 price forecast, based on 2.5 times estimated sales. The article links the move to Neuronetics’ 2024 Greenbrook TMS acquisition, adding TMS and Spravato. It cites Q1 results: loss of 16 cents and sales of $34.454M.
4 min readNeuronetics, Inc. (STIM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d226320dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 SEPARATION AGREEMENT This Separation Agreement (the “ Agreement ”) is entered into by and between NEURONETICS, INC., a Delaware corporation, and W. ANDREW MACAN (“ Executive ”) (together, “ the Parties ”) to set forth their
2 min readChernett Jorey purchased 35,000 shares of Neuronetics, Inc. (STIM) at $1.78 on 2026-07-14.
1 min readNeuronetics, Inc. (STIM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001227636 0001227636 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2
2 min readPRISM MarketView highlighted seven public companies developing mental health therapies, devices, and digital platforms during National Mental Health Awareness Month. Featured firms include Helus Pharma (HELP), GH Research (GHRS), AtaiBeckley (ATAI), Definium Therapeutics (DFTX), BrainsWay (BWAY), Neuronetics (STIM), and Talkspace (TALK), spanning psychedelic-derived treatments, TMS, and virtual care.
4 min readThis page on Stock Titan offers a comprehensive resource for Neuronetics (STIM) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights how Neuronetics, a medical technology company focusing on NeuroStar Advanced Therapy and Greenbrook TMS treatment centers, reports its financial performance, capital structure, and risks. The article also provides summaries of recent filings, including insider transactions, leadership changes, and financial results.
3 min readNeuronetics, Inc. announced inducement awards granted to six new non-executive employees under Nasdaq Listing Rule 5635(c)(4). These awards, primarily Restricted Stock Units (RSUs), were approved by the Compensation Committee as a material inducement for their employment. The vesting of these awards is contingent upon the employees' continued service with the company through the specified vesting dates.
2 min readNeuronetics, Inc. (NASDAQ: STIM) announced it will release its first quarter 2026 financial and operating results before market open on Tuesday, May 5, 2026. The company will also host a conference call at 8:30 a.m. Eastern Time on the same day to discuss these results.
3 min read
